Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome.

Replication and Characterization of Association between ABO SNPs and Red Blood Cell Traits by Meta-Analysis in Europeans. PLoS One (2016) 0.75

Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2014) 26.76

Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07

GenABEL: an R library for genome-wide association analysis. Bioinformatics (2007) 18.10

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Whole-genome genotyping with the single-base extension assay. Nat Methods (2006) 6.66

Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem (1998) 6.14

Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered (2003) 5.06

Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet (1999) 4.33

Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res (2004) 3.93

5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet (2006) 3.01

Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet (2008) 2.85

The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood (1987) 2.84

Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA (2001) 2.37

Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 2.18

Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet (1999) 1.70

Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation (2003) 1.67

The ABO blood group system revisited: a review and update. Immunohematology (2009) 1.51

The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med (2001) 1.34

Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol (2002) 1.27

A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet (2012) 1.23

Effects of normalization on quantitative traits in association test. BMC Bioinformatics (2009) 1.07

Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart (2007) 1.04

Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am J Cardiol (2006) 1.02

A quantitative difference in the activity of blood group A-specific N-acetylgalactosaminyltransferase in serum from A 1 and A 2 human subjects. Biochem Biophys Res Commun (1971) 1.01

Increased inflammatory responses of persons of blood group O to Helicobacter pylori. J Infect Dis (2000) 0.97

Biological and clinical aspects of ABO blood group system. J Med Invest (2008) 0.95

Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol (2006) 0.92

Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies. Thromb Haemost (2010) 0.88

Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome. Thromb Res (2006) 0.86

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J (2005) 0.83

Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor. Br J Haematol (2000) 0.81

Association of blood groups with prognosis in acute coronary syndrome. Pol Arch Med Wewn (2013) 0.79

Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med (2005) 0.78

Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol (2014) 2.18

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol (2016) 1.43

Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J (2014) 0.93

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother (2015) 0.80

Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. Am Heart J (2014) 0.78

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol (2015) 0.77

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart (2016) 0.76

Estimating pre-traumatic quality of life in patients with surgically treated acetabular fractures and pelvic ring injuries: Does timing matter? Injury (2015) 0.76

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol (2017) 0.76

Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart (2015) 0.75

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace (2017) 0.75

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc (2017) 0.75

Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med (2017) 0.75

Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights From the ARISTOTLE Trial. Am J Med (2017) 0.75

The relative contribution of DNA methylation and genetic variants on protein biomarkers for human diseases. PLoS Genet (2017) 0.75

Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovasc Drugs Ther (2017) 0.75

Gene-environment interaction study for BMI reveals interactions between genetic factors and physical activity, alcohol consumption and socioeconomic status. PLoS Genet (2017) 0.75

Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol (2016) 0.75

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J (2016) 0.75